Table 2

Characterization of autologous WT1 CTLs used for treatment of patients with ovarian cancer

Dose cohort group	Patient study ID	HLA alleles of autologous WT1 CTLs infused to patients with ovarian cancer										Characterization of WT1 CTLs
Dose cohort group	Patient study ID	A	A	B	B	C	C	DRB 1	DRB 1	DBQ 1	DBQ 1	HLA restricting alleles of WT1 CTLs	Immunodominant peptides	Absolute number of EBV CTLp cells /10⁶ CTLs	Absolute number of WT1 CTLp cells /10⁶ CTLs	Absolute number of WT1 reactive IFN-y CD3 cells /10⁶ CTLs	Dominant population of cells	Total dose of clonogenic WT1 CTLp infused/m²
I	001	2301	3101	3502	4403	0401	0401	0403	0701	0305	0303	A2301	_238-246WNQNMLGAT	1.53	1.33	30 600	CD8	6.65
I	002	0201	0201	5001	5701	0602	0602	0701	1305	0202	0301	B5001	_238-246WNQNMLGAT	1.28	1.28	29 000	CD8	6.4
I	003	0201	2601	2705	3801	0102	1203	0103	0402	0401	0302	B3801	_(-51)-(-42)LRSSGPGCLQQ _46-54 SAYGSLGGP _94-102VHFSGQFTG	90 909	58 883	28 100	CD8	5 888 330
II	004	0201	6801	2705	2707	01 XX	02 XX	0701	1301	0202	0603	NA	_238-246WNQNMLGAT	27 027	2.48	24 800	CD8	148.8
II	005	0101	0201	0801	5101	0701	1402	0101	0301	0501	0201	A0201	_(-75)-(-67)AILDFLLLQ	1.28	1074	82 800	CD8	85 920
II	006	0201	2301	1801	4403	0501	401	0301	0701	0201	0202	C0501 A2301*	_187-201SLGEQQYSVPPPVYG _235-249CMTWNQMNLGATLKG _203-217HTPTDSCTGSQALLL _251-265AAGSSSSVKWTEGQS _331-345NKRYFKLSHLQMHSR _347-361HTGEKPYQCDFKDCE	1001	6289	63 600	CD8	251 560
III	007	1101	3001	4402	3501	0602	0401	0401	0101	0301	0501	NA	NA	3571	1.54	NA	CD8	154
III	008	0301	3101	4001	3701	0602	0304	0404	1001	0302	0501	B4001	NA	199 756	405	0.1	CD8	141 750
III	009	0101	2501	1801	0702	0702	1203	1501	1501	0602	0603	NA	NA	NA	NA	NA	CD4	NA
III	010	0101	0301	3503	5201	0401	1202	1201	1501	0301	0601	A0101	NA	23.7	1.28	0.1	CD4/CD8	256
IV	011	0101	3201	2703	4001	0202	0304	0401	1201	0301	0302	A3201	NA	1268	178	1	CD8/CD4	53 400
IV	012	0201	2902	3502	4403	0401	1601	0701	1104	0202	0301	A0201	_(-75)-(-67)AILDFLLLQ	2.48	18.3	23 900	CD8	7320

*HLA restricting alleles determined for patient #006: WT1 CTLs recognized WT1 primarily via HLA-C0501 allele with subdominant recognition of HLA-A2301 target loaded with WT1 total pool. Restricting HLA allele for each of the identified epitopes could not be tested individually due to lack of suitable targets at the time of testing.
CTLp, CTL precursors; CTLs, cytotoxic T lymphocytes; EBV, Epstein-Barr virus; WT1, Wilms’ tumor protein 1.